V. Jooste, L. Remontet, M. Colonna, A. Belot, G. Launoy et al., Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010, European Journal of Cancer Prevention, vol.20, issue.5, pp.375-80, 2011.
DOI : 10.1097/CEJ.0b013e3283465426
URL : https://hal.archives-ouvertes.fr/hal-00697965

L. Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, 2012, Global cancer statistics, pp.87-108, 2012.
DOI : 10.1038/nrc1948

N. Ferrara, K. Hillan, H. Gerber, and W. Novotny, Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nature Reviews Drug Discovery, vol.81, issue.5, pp.391-400, 2004.
DOI : 10.1016/S1359-6349(03)91004-4

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.99, issue.21, pp.669-76, 2003.
DOI : 10.1073/pnas.152324099

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2377, 2004.
DOI : 10.1056/NEJMoa032691

S. Temraz, D. Mukherji, R. Alameddine, and A. Shamseddine, Methods of overcoming treatment resistance in colorectal cancer, Critical Reviews in Oncology/Hematology, vol.89, issue.2, pp.217-247, 2014.
DOI : 10.1016/j.critrevonc.2013.08.015

M. Caulet, T. Lecomte, O. Bouché, J. Rollin, V. Gouilleux-gruart et al., Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients, Clinical Pharmacokinetics, vol.108, issue.5, 2016.
DOI : 10.1038/bjc.2013.79

G. Cui, A. Yuan, R. Goll, and J. Florholmen, IL-17A in the tumor microenvironment of the human colorectal adenoma???carcinoma sequence, Scandinavian Journal of Gastroenterology, vol.32, issue.4, pp.1304-1316, 2012.
DOI : 10.1371/journal.pone.0034959

J. Liu, Y. Duan, X. Cheng, X. Chen, W. Xie et al., IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma, Biochemical and Biophysical Research Communications, vol.407, issue.2, pp.348-54, 2011.
DOI : 10.1016/j.bbrc.2011.03.021

Y. Shi, H. Lin, J. Cui, H. Qi, J. Florholmen et al., The Role of Interleukin-17A in Colorectal Tumorigenesis, Cancer Biotherapy & Radiopharmaceuticals, vol.28, issue.6, pp.429-461, 2013.
DOI : 10.1089/cbr.2012.1396

J. Tseng, C. Yang, S. Liang, R. Liu, S. Yang et al., Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases, Clinical Cancer Research, vol.20, issue.11, pp.2885-97, 2014.
DOI : 10.1158/1078-0432.CCR-13-2162

D. Wu, P. Wu, Q. Huang, Y. Liu, J. Ye et al., Interleukin-17: A Promoter in Colorectal Cancer Progression, Clinical and Developmental Immunology, vol.26, issue.6, p.436307, 2013.
DOI : 10.4049/jimmunol.1003251

A. Chung, X. Wu, G. Zhuang, H. Ngu, I. Kasman et al., An interleukin-17???mediated paracrine network promotes tumor resistance to anti-angiogenic therapy, Nature Medicine, vol.59, issue.9, pp.1114-1137, 2013.
DOI : 10.1177/002215540305100503

F. Lotti, A. Jarrar, R. Pai, M. Hitomi, J. Lathia et al., Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A, The Journal of Experimental Medicine, vol.133, issue.13, pp.2851-72, 2013.
DOI : 10.1073/pnas.0915135107
URL : http://jem.rupress.org/content/jem/210/13/2851.full.pdf

K. Wang, M. Kim, D. Caro, G. Wong, J. Shalapour et al., Interleukin-17 Receptor A Signaling in Transformed Enterocytes Promotes Early Colorectal Tumorigenesis, Immunity, vol.41, issue.6, pp.1052-63, 2014.
DOI : 10.1016/j.immuni.2014.11.009

W. Ouyang, J. Kolls, and Y. Zheng, The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation, Immunity, vol.28, issue.4, pp.454-67, 2008.
DOI : 10.1016/j.immuni.2008.03.004

L. Steinman, A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell???mediated tissue damage, Nature Medicine, vol.59, issue.2, pp.139-184, 2007.
DOI : 10.4049/jimmunol.165.11.6107

B. Yang, H. Kang, A. Fung, H. Zhao, T. Wang et al., The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis, Mediators of Inflammation, vol.31, issue.1, article 795, p.623759, 2014.
DOI : 10.1016/j.leukres.2013.06.022

W. Zou and N. Restifo, TH17 cells in tumour immunity and immunotherapy, Nature Reviews Immunology, vol.8, issue.4, pp.248-56, 2010.
DOI : 10.4049/jimmunol.174.5.2591
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242804/pdf

P. Miossec and J. Kolls, Targeting IL-17 and TH17 cells in chronic inflammation, Nature Reviews Drug Discovery, vol.56, issue.10, pp.763-76, 2012.
DOI : 10.1002/art.22733

Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, Functional Specialization of Interleukin-17 Family Members, Immunity, vol.34, issue.2, pp.149-62, 2011.
DOI : 10.1016/j.immuni.2011.02.012

K. Hirota, H. Ahlfors, J. Duarte, and B. Stockinger, Regulation and function of innate and adaptive interleukin-17-producing cells, EMBO reports, vol.207, issue.2, pp.113-133, 2011.
DOI : 10.1084/jem.20100703

S. Chang and C. Dong, IL-17F: Regulation, signaling and function in inflammation, Cytokine, vol.46, issue.1, pp.7-11, 2009.
DOI : 10.1016/j.cyto.2008.12.024
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663007/pdf

Z. Tong, X. Yang, H. Yan, W. Liu, X. Niu et al., A Protective Role by Interleukin-17F in Colon Tumorigenesis, PLoS ONE, vol.15, issue.4, p.34959, 2012.
DOI : 10.1371/journal.pone.0034959.s004

K. Nemati, H. Golmoghaddam, S. Hosseini, A. Ghaderi, and M. Doroudchi, Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression, Gene, vol.561, issue.1, pp.88-94, 2015.
DOI : 10.1016/j.gene.2015.02.014

I. Omrane, R. Marrakchi, O. Baroudi, A. Mezlini, H. Ayari et al., Significant association between interleukin-17A polymorphism and colorectal cancer, Tumor Biology, vol.7, issue.4, pp.6627-6659, 2014.
DOI : 10.1371/journal.pone.0034959

I. Omrane, O. Baroudi, K. Bougatef, A. Mezlini, A. Abidi et al., Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer, Immunology Letters, vol.158, issue.1-2, pp.189-94, 2014.
DOI : 10.1016/j.imlet.2014.01.002

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-221, 2000.
DOI : 10.1093/jnci/92.3.205

X. Wu, Z. Zeng, C. B. Yu, J. Xue, L. Hao et al., Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer, International Journal of Cancer, vol.69, issue.1, pp.86-92, 2010.
DOI : 10.1158/0008-5472.CAN-09-0596

T. Wrobel, K. Gebura, B. Wysoczanska, B. Jazwiec, O. Dobrzynska et al., IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia, Journal of Cancer Research and Clinical Oncology, vol.158, issue.9, pp.1551-1556, 2014.
DOI : 10.1111/j.1365-2249.2009.04011.x

J. Wang, K. Xu, J. Wu, C. Luo, Y. Li et al., The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers, BMC Cancer, vol.117, issue.1, p.418, 2012.
DOI : 10.1182/blood-2010-11-317321

B. Giantonio, P. Catalano, N. Meropol, O. Dwyer, P. Mitchell et al., Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200, Journal of Clinical Oncology, vol.25, issue.12, pp.1539-1583, 2007.
DOI : 10.1200/JCO.2006.09.6305

H. Hurwitz, N. Tebbutt, F. Kabbinavar, B. Giantonio, Z. Guan et al., Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials, The Oncologist, vol.18, issue.9, pp.1004-1016, 2013.
DOI : 10.1634/theoncologist.2013-0107

P. Wu, D. Wu, C. Ni, J. Ye, W. Chen et al., ????T17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer, Immunity, vol.40, issue.5, pp.785-800, 2014.
DOI : 10.1016/j.immuni.2014.03.013

G. Murugaiyan and B. Saha, Protumor vs Antitumor Functions of IL-17, The Journal of Immunology, vol.183, issue.7, pp.4169-75, 2009.
DOI : 10.4049/jimmunol.0901017

D. Chan, N. Pavlakis, J. Shapiro, T. Price, C. Karapetis et al., Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta- Analysis of the Literature, PLoS One, vol.10, issue.8, p.135599, 2015.

K. Wang and M. Karin, Tumor-Elicited Inflammation and Colorectal Cancer, Adv Cancer Res, vol.128, pp.173-96, 2015.
DOI : 10.1016/bs.acr.2015.04.014

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger et al., Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research, vol.71, issue.4, pp.1263-71, 2011.
DOI : 10.1158/0008-5472.CAN-10-2907

Y. Lin, J. Xu, H. Su, W. Zhong, Y. Yuan et al., Interleukin-17 is a favorable prognostic marker for colorectal cancer, Clinical and Translational Oncology, vol.7, issue.12, pp.50-56, 2015.
DOI : 10.1371/journal.pone.0030806

L. Gouvello, S. Bastuji-garin, S. Aloulou, N. Mansour, H. Chaumette et al., High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas, Gut, vol.57, issue.6, pp.772-781, 2008.
DOI : 10.1136/gut.2007.123794
URL : https://hal.archives-ouvertes.fr/inserm-00284889

Z. Dai, T. Zhang, S. Lin, W. Zhang, J. Liu et al., Role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in risk of cancer development: an updated meta-analysis, Scientific Reports, vol.21, issue.1, p.20439, 2016.
DOI : 10.1002/sim.1186

S. Punt, J. Langenhoff, H. Putter, G. Fleuren, A. Gorter et al., The correlations between IL-17??vs. Th17 cells and cancer patient survival: a systematic review, OncoImmunology, vol.162, issue.2, p.984547, 2015.
DOI : 10.7326/0003-4819-151-4-200908180-00135